<DOC>
	<DOCNO>NCT00615524</DOCNO>
	<brief_summary>This study conduct compare efficacy safety exemestane alone combination pazopanib postmenopausal woman hormone receptor positive breast cancer fail therapy tamoxifen , anastrazole letrozole .</brief_summary>
	<brief_title>Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Subjects must measurable disease OR must evaluable disease progression Age &gt; /= 18 year . Postmenopausal woman Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . Histologically cytologically confirm ER and/or PgR positive carcinoma breast unresectable , locally advanced and/or metastatic disease Subjects must receive prior hormonal therapy treatment breast cancer ( anastrozole , letrozole , tamoxifen ) Adequate hematologic , hepatic , renal function Prior use exemestane pazopanib Premenopausal woman Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity . Prior therapy VEGF inhibitor . Use investigational agent , include investigational anticancer agent , within 28 day 5 halflives , whichever longer , prior first dose investigational product . Evidence recurrence active disease prior malignancy . Clinically significant gastrointestinal abnormality may increase risk GI bleed affect absorption investigational product ( ) . Presence uncontrolled infection . History major cardiovascular condition within past 6 month : Poorly control hypertension History cerebrovascular accident , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Prior major surgery trauma within 28 day prior first dose investigational product and/or presence nonhealing wound , fracture , ulcer Evidence active bleeding bleeding tendency .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Advanced</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>GW786034</keyword>
	<keyword>Exemestane</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Health-Related Quality Life</keyword>
</DOC>